Atrium Innovations Inc. a globally recognized leader in the development, manufacturing and commercialization of innovative, science-based natural health products, announced today the successful completion of the previously announced plan of arrangement providing for the acquisition of all of the outstanding common shares of Atrium by corporations backed by the Permira funds and the acquisition by the Corporation of all of its outstanding 5.75% convertible unsecured subordinated debentures.
Pursuant to the Arrangement, the former holders of Atrium Shares and Caisse de dépôt et placement du Québec will receive, for each Atrium Share held, $24.00 in cash, and the former holders of Atrium Debentures will receive, for each $1,000 principal amount of Atrium Debentures, a cash amount of $1,150.09 (representing the aggregate of $1,000 in principal amount, accrued and unpaid interest on such principal amount to, but excluding, February 13, 2014, and the interest that would otherwise be payable thereon from and including February 13, 2014 to, but excluding, March 15, 2014, as well as the applicable “make whole premium” on the basis of a stock price of $24.00).
Click below to download the full release.
